New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
10:00 EDTUNH, ESYJY, VOD, ATML, FUEL, NUS, XXIA, AET, THOR, RLOC, NSPH, CPA, ANAD, SD, PERI, MNTXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ANADIGICS (ANAD) downgraded to Hold from Buy at Craig-Hallum... Aetna (AET) downgraded to Neutral from Buy at Goldman... Atmel (ATML) downgraded to Neutral from Buy at BofA/Merrill... Copa Holdings (CPA) downgraded to Equal-Weight from Overweight at Evercore... Ixia (XXIA) downgraded to Hold from Buy at Jefferies... Manitex (MNTX) downgraded to Neutral from Buy at Global Hunter... Nanosphere (NSPH) downgraded at Craig-Hallum... Nu Skin (NUS) downgraded to Neutral from Overweight at JPMorgan... Perion Network (PERI) downgraded to Hold from Buy at Needham... ReachLocal (RLOC) downgraded to Neutral from Overweight at Piper Jaffray... Rocket Fuel (FUEL) downgraded to Equal Weight from Overweight at First Analysis... SandRidge Energy (SD) downgraded to Neutral from Accumulate at Global Hunter... Thoratec (THOR) downgraded to Neutral from Buy at BTIG... UnitedHealth (UNH) downgraded to Buy from Conviction Buy at Goldman... Vodafone (VOD) downgraded to Market Perform from Outperform at Raymond James... easyJet (ESYJY) downgraded to Equal Weight from Overweight at Barclays.
News For ANAD;AET;ATML;CPA;XXIA;MNTX;NSPH;NUS;PERI;RLOC;FUEL;SD;THOR;UNH;VOD;ESYJY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 22, 2015
07:02 EDTTHORSt. Jude Medical sees Thoratec deal accretive to adjusted EPS in 2016
Subscribe for More Information
07:02 EDTTHORSt. Jude Medical to acquire Thoratec for $63.50 per share, deal valued at $3.4B
St. Jude Medical (STJ) and Thoratec (THOR) announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a cash transaction valued at approximately $3.4B, net of cash acquired. The all-cash transaction represents a premium of 40.1 percent compared to $45.34, Thoratec's volume-weighted average trading price for the 30 trading day period ending July 17, 2015, and a 35.4 percent premium to the closing price on Thoratec's last unaffected trading date on July 17, 2015 of $46.89. The transaction is expected to be completed in the fourth quarter of 2015. Under the terms of the merger agreement, Thoratec shareholders will receive $63.50 in cash, without interest, for each share of Thoratec common stock they own. The transaction is conditioned upon, among other things, Thoratec shareholder approval, regulatory approvals and other customary closing conditions. The transaction is not conditioned on financing. St. Jude Medical intends to fund the transaction through proceeds from additional bank term loan debt and senior unsecured notes. St. Jude Medical is committed to maintaining a strong investment grade rating. The merger agreement includes a “go-shop” period, during which Thoratec will actively solicit alternative proposals from third parties for the next 30 days continuing through August 20, 2015. The merger agreement provides for Thoratec to pay a termination fee of approximately $30 million to St. Jude Medical if Thoratec terminates the merger agreement in connection with a superior proposal that arose during the go-shop period and a termination fee of approximately $111 million if Thoratec terminates the merger agreement in connection with a superior proposal that arose following the go-shop period. There can be no assurance that this process will result in a superior proposal. Thoratec does not intend to disclose developments with respect to the solicitation process unless and until its Board of Directors has made a decision with respect to any potential superior proposal. This transaction is expected to be accretive to adjusted earnings per share in 2016. St. Jude Medical also expects the combined company to capture revenue and technology synergies following the completion of this transaction. This acquisition positions St. Jude Medical to enter new markets totaling more than $1 billion that are expected to grow approximately 10 percent annually, benefitting St. Jude Medical’s sales growth profile beginning in 2016. Bank of America Merrill Lynch is acting as financial advisor to St. Jude Medical and has also provided fully committed financing. Gibson, Dunn & Crutcher LLP is serving as legal counsel to St. Jude Medical. Guggenheim Securities is acting as financial advisor to Thoratec, and Latham & Watkins LLP is serving as legal counsel. Centerview Partners provided a fairness opinion to the Board of Directors of Thoratec in connection with the transaction.
07:00 EDTTHORSt. Jude Medical to acquire Thoratec for $63.50 per share, deal valued at $3.4B
Subscribe for More Information
06:28 EDTSDSandRidge Energy coverage assumed with an Underperform at Credit Suisse
Subscribe for More Information
July 21, 2015
16:28 EDTTHOROn The Fly: Top stock stories for Tuesday
Subscribe for More Information
15:08 EDTTHORThoratec reaches all-time high after report of St. Jude takeover
Subscribe for More Information
14:52 EDTTHORThoratec could possibly get $65-$70 per share in takeover, says Northland
Subscribe for More Information
13:56 EDTTHORSt. Jude Medical bid for Thoratec makes strategic sense, says JPMorgan
Subscribe for More Information
12:40 EDTTHORSt. Jude in talks to acquire Thoratec, Bloomberg reports
St. Jude Medical (STJ) is in talks to acquire Thoratec (THOR), Bloomberg reports, citing people familiar with the situation. Talks are ongoing and could still fall apart as no deal has been reached, Bloomberg adds. Thoratec shares spiked early in today's session, but a catalyst for the move was unclear before the Bloomberg report. Shares of the medical device maker focused on advanced heart failure patients are up $9.52 to $58.33 in midday trading. Its close competitor HeartWare (HTWR) is now up $5.53 to $84.70. Shares of St. Jude are up 4 to $76.61. Reference Link
12:33 EDTTHORThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
12:29 EDTTHORSt. Jude Medical in talks to acquire Thoratec, Bloomberg reports
Subscribe for More Information
12:21 EDTTHOROn The Fly: Top stock stories at midday
Subscribe for More Information
10:20 EDTTHORCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
10:14 EDTTHORHigh option volume stocks:
Subscribe for More Information
10:12 EDTTHORThoratec calls active on sharp rally
Thoratec August 55 and 65 calls are active on 260 contracts (50 puts). August call option implied volatility is at 55, September is at 50; compared to its 52-week range of 24 to 51. Active calls suggests traders taking positions for price movement.
10:01 EDTNUSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:58 EDTTHORThoratec jumps 14% to $55.82 in early trading
Subscribe for More Information
July 20, 2015
16:41 EDTNUSNu Skin initiated with a Neutral at Sterne Agee CRT
Subscribe for More Information
14:22 EDTVODEarnings Watch: Verizon to report Q2 results after AOL acquisition
Verizon Communications (VZ) is expected to report second quarter earnings before the market open on Tuesday, July 21, with a conference call scheduled for 8:30 am ET. Verizon is a holding company providing communications, information and entertainment. EXPECTATIONS: Analysts are looking for earnings per share of $1.01 on revenue of $32.45B, according to First Call. The consensus range for EPS is 93c-$1.05 on revenue of $31.75B-$33.0B. LAST QUARTER: Verizon reported first quarter EPS of $1.02 against estimates for 95c on revenue of $32B against estimates for $32.27B. Verizon Wireless had 565,000 retail postpaid net additions in Q1, a 4.8% increase compared with first-quarter 2014. At the end of Q1, the company had 108.6M retail connections, a 5.1% year-over-year increase, and had 102.6M retail postpaid connections. The company added 621,000 4G smartphones to its customer base in Q1. In light of a net decline in 3G smartphones, overall smartphone growth totaled 247,000. The company also added 820,000 4G tablets and reported net declines of 385,000 basic phones and 188,000 prepaid devices in Q1. 4G devices now constitute approximately 70% of the retail postpaid connections base, up from 49% a year ago – with the 4G LTE network handling about 86% of total wireless data traffic in Q1. At 1.03% in Q1, retail postpaid churn improved both sequentially and year over year. Retail postpaid smartphone customer churn was less than 0.9%. Verizon added 133K net new FiOS Internet, and 90K net new FiOS Video connections in Q1. Verizon had totals of 6.7M FiOS Internet and 5.7M FiOS Video connections at the end of the first quarter, representing year-over-year increases of 9.4% and 7.9%, respectively. CEO Lowell McAdam said, “We are confident in our ability to maintain momentum and continue to add value for customers and shareholders.” On May 12, Verizon announced it would acquire AOL for $50 per share, or $4.4B. The transaction was completed on June 23. On May 19, speaking at the JPMorgan Global Technology, Media and Telecom Conference, CFO Fran Shammo said he expects net phone additions in Q2. ANALYST REACTION: Street research has been mostly mixed in the weeks leading up to Verizon’s Q2 earnings report. On May 12, Macquarie downgraded Verizon to Underperform from Neutral with a $45 price target to reflect a weaker 2016 and 2017 earnings outlook. The firm's analyst believed management has made a series of questionable strategic moves beginning with the Vodafone (VOD) deal that will depress earnings. Recent advertising promotions are likely to pressure 2015 margins and ARPU and LTE capacity issues are expected in certain markets later in the year. Macquarie is surprised Verizon shares have held in around $50 with treasury yields rising and increasing Q2 promotions and does not believe this is sustainable ahead of a reset in consensus estimates. Conversely, on July 9, Stifel resumed coverage of Verizon with a Buy rating and price target of $60 per share. PRICE ACTION: Verizon’s shares are down about 3% since the company's Q1 report. Over the past twelve months, they are down about 5.7%. In afternoon trading ahead of Tuesday's Q2 report, Verizon’s shares are up 0.6%.
07:41 EDTVODBT CEO: Company split doesn't solve problems, Telegraph reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use